Exosomes, carriers to transfer endogenous molecules, derived from bone marrow-derived mesenchymal stem cells (BMSCs) have been reported to play a role in the progression of bladder cancer. Here we aimed to test the functional mechanism of microRNA-9-3p (miR-9-3p)-containing exosomes derived from BMSCs in bladder cancer. BMSCs were cocultured with bladder cancer cells, and exosomes secreted from BMSCs were identified. Next, the expression of miR-9-3p and endothelial cell-specific molecule 1 (ESM1) in bladder cancer tissues and cells was determined. Then effects of miR-9-3p and ESM1 via BMSC-derived exosomes on bladder cancer cell viability, migration, invasion, and apoptosis were determined by loss-and gain-of-function experiments and on in vivo tumor growth, and metastasis was assessed in nude mice. miR-9-3p expression was decreased and ESM1 was increased in bladder cancer. BMSCs inhibited bladder cancer cell viability, migration, and invasion, and induced apoptosis, whereas the addition of exosome secretion inhibitor GW4869 achieved the opposite effects. Moreover, exosomal miR-9-3p upregulation or ESM1 silencing suppressed bladder cancer cell viability, migration, and invasion; induced cell apoptosis; and inhibited in vivo tumor growth and metastasis. Taken together, BMSCderived exosomal miR-9-3p suppressed the progression of bladder cancer through ESM1 downregulation, offering a potential novel therapeutic target for bladder cancer therapy.
INTRODUCTION
Bladder cancer is one of the most frequent human cancers developed via papillary and nonpapillary tracks corresponding to different clinical forms. 1 Recent estimates indicate that 80,470 new bladder cancer cases are diagnosed annually, accounting for 17,670 deaths worldwide in 2019. 2 Good outcomes of bladder cancer patients rely on early awareness of hematuria, early diagnosis, personalized therapeutic intervention, and follow-up. 3 Recently, a comprehensive genomic analysis based on data from The Cancer Genome Atlas (TCGA) data-base confirmed that multiple subtypes of bladder cancers are induced by different genetic changes. 4 Importantly, changes in expression of mRNAs, long non-coding RNAs (lncRNAs), and microRNAs (miRNAs) are associated with changes in epithelial-mesenchymal transition (EMT) status, carcinoma scores, histologic characteristics, and survival in bladder cancers. 5 Therefore, it is important to understand molecular changes in bladder cancer to improve both diagnosis and treatment.
Endothelial cell-specific molecule 1 (ESM1), also known as endocan, has angiogenic and inflammatory properties that may affect vascular permeability. 6 Interestingly, ESM1 is found to be highly expressed in blood vessels from invasive bladder cancer tissues. 7 Additionally, serum and urinary ESM1 levels in bladder cancer patients are higher than that of healthy subjects. 8 However, how ESM1 is involved in bladder cancer development remains unclear. miRNAs, small non-coding RNAs, suppress translational expression and stability of mRNAs, and also control cellular processes such as cell-cycle regulation, cellular differentiation, and apoptosis. Dysregulation of miRNAs has been shown to play an essential role in the development and progression of cancers. 9 Several anti-oncologic miRNAs such as miR-145, miR-143, and miR-125b are downregulated in bladder cancer, whereas some oncogenic miRNAs such as Mouse bone marrow-derived mesenchymal stem cells (BMSCs) were cocultured with bladder cancer cell line UMUC-3 in a Transwell chamber to determine the effects of BMSCs on bladder cancer cell viability, apoptosis, migration, and invasion (Figures 2A-2D ). It was found that compared with the single culture of UMUC-3, their coculture decreased cell viability, invasion, and migration, and increased apoptosis in UMUC-3 cells (p < 0.05). Meanwhile, the same experiment was conducted between human BMSCs and bladder cancer cell line UMUC-3, with similar results obtained ( Figure S1 ). These results suggested that BMSCs may have inhibitory effects on bladder cancer cells.
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Exosome Secreted from BMSCs Affects Biological Functions of Bladder Cancer Cells
The secretion from BMSCs was observed using a transmission electron microscope (HT7700; Beijing SJC Science and Trade, Beijing, China). BMSC secretions had typical exosome morphologies, characterized by irregular sizes and approximate diameter of 30-100 nm ( Figure 3A ). These secretions had a spherical structure surrounded by a lipid bilayer membrane, which was stained dark outside and lightly stained inside with protein-like substances. Exosome size was further determined using a nanoparticle tracking analyzer (NTA). It was found that the majority of exosomes had a diameter of approximately 120 nm, ranging from 30 to 150 nm. The most abundant exosome size was around 115 nm in diameter and at 1.7 Â 10 11 particles/L ( Figure 3B ). For further verification, the expression of exosomal surface marker proteins was determined by western blot analysis. CD9, CD63, CD81, Alix, and TSG101 were all found in exosomes produced by BMSCs, yet there was no presence of nonspecific protein calnexin (Figure 3C ). These results strongly suggested that BMSCs secreted exosomes.
Under a confocal microscope, exosomes labeled with PKH26 were cocultured with UMUC-3 cells. After 30 min of coculture, slight red fluorescence of PKH26-labeled exosomes was observed in UMUC-3 cells, suggesting fewer exosomes were present in UMUC-3 cells. With the extension of coculture time, more and more UMUC-3 cells revealed red fluorescence, demonstrating the increase of PKH26labeled exosomes taken up by UMUC-3 cells. After 24 h of coculture, this was especially clear ( Figure 3D ). Hence BMSC-derived exosome could be taken up by bladder cancer cells.
To study the effect of exosomes on biological functions of bladder cancer cells in vitro, we added a specific exosome secretion inhibitor, GW4869, to the coculture system to assess the release of exosomes. The same concentration of DMSO was added as control. Bicinchoninic acid (BCA) assay, NTA, and western blot analysis found that when compared with the addition of DMSO, the addition of GW4869 decreased total protein concentration and expression of CD9, CD63, CD81, Alix, and TSG101 (p < 0.05) ( Figures 3E-3I ), suggesting decreased exosome secretion. Meanwhile, the addition of GW4869 also increased cell viability, migration, and invasion in bladder cancer cells cocultured with BMSCs.
Next, to exclude other potential disturbances on cells, we examined the effect of GW4869 on single UMUC-3 cells. The addition of GW4869 did not impact cell viability, migration, and invasion of bladder cancer cells (p > 0.05) ( Figure S2 ). These results suggest that exosomes secreted by BMSCs may be responsible for the effects of BMSCs on bladder cancer cells.
Exosomal miR-9-3p Inhibits Viability, Migration, and Invasion while Promoting Apoptosis in Bladder Cancer Cells miR-9-3p in BMSCs was overexpressed to determine its effects on viability, apoptosis, migration, and invasion of bladder cancer cells. Next, exosomes were isolated and purified. qRT-PCR verified that exosomal miR-9-3p expression was increased following treatment with Exo-miR-9-3p (BMSC-derived exosomes treated with miR-9-3p mimic) (p < 0.05) ( Figure 4A ). A series of in vitro experiments including 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, flow cytometry, scratch test, and Transwell assay were conducted to assess viability, apoptosis, migration, and invasion in bladder cancer cells ( Figures 4B-4E ). It was revealed that cell viability, migration, and invasion were decreased, whereas apoptosis was increased following the treatment of Exo-miR-9-3p (p < 0.05). Additionally, western blot analysis detected that protein expression levels of proliferation-associated factors (Ki67 and proliferating cell nuclear antigen [PCNA]) and invasion-associated factors (matrix metalloprotease [MMP]-2 and MMP-9) were decreased following the treatment of Exo-miR-9-3p (p < 0.05) ( Figure 4F ). Therefore, exosomal miR-9-3p inhibited viability, migration, and invasion, and promoted apoptosis in bladder cancer cells.
miR-9-3p Elevation Impairs Viability, Migration, Invasion, and Apoptosis of Bladder Cancer Cells
In order to investigate the effect of miR-9-3p on the biological functions of bladder cancer cells, miR-9-3p was overexpressed and decreased in bladder cancer cell line UMUC-3 to detect the proliferation, migration, invasion, and apoptosis of bladder cancer cells. It was observed that, when compared with matched controls, the UMUC-3 cell viability, migration, and invasion were decreased and apoptosis was increased in the treatment of mimic miR-9-3p, whereas opposite results were observed in the treatment of inhibitor miR-9-3p (p < 0.05) ( Figures 5A-5H ). All of the results indicated that upregulation of miR-9-3p could inhibit the viability, migration, and invasion, and promote the apoptosis of bladder cancer cells.
miR-9-3p Targets ESM1, and ESM1 Silencing Prevents Bladder Cancer Progression
Previous microarray analysis indicated that ESM1 might be a target gene of miR-9-3p. In the current study, a binding site was identified between miR-9-3p and ESM1 using TargetScan ( Figure S3A ), which was then verified by dual-luciferase reporter gene assay (Figure S3B ). It was found that in the presence of miR-9-3p overexpression (miR-OE) (cells treated with mimic miR-9-3p), the luciferase activity of ESM1-5 0 UTR (hsa_miR-9-3p) (wild-type [WT]) showed a decline, whereas that of ESM1-5 0 UTR (hsa_miR-9-3p) (mutant [MUT]) did not alter. These results further demonstrated that ESM1 was a target gene of miR-9-3p.
qRT-PCR was used to detect the expression of ESM1 in bladder cancer cells. The results showed that the expression of ESM1 in bladder cancer cells was upregulated (p < 0.05) ( Figure 6A ). ESM1 was decreased to determine its effects on bladder cancer cell viability, migration, invasion, and apoptosis ( Figures  6B-6E ). It was revealed that cell viability, migration, and invasion were retarded, whereas apoptosis was enhanced after silencing of ESM1.
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Next, tumor formation in nude mice was conducted to evaluate the effect of si-ESM1 on tumor growth. It was found that ESM1 expression was decreased after ESM1 was knocked down, and its silencing weakened tumor growth, tumor volume, and tumor weight (p < 0.05) ( Figures 6F-6I ). Concurrently, immunofluorescent staining found that silencing of ESM1 reduced the expression of MMP-2 and MMP-9 (p < 0.05) ( Figure 6J ). H&E staining was then used to examine tumor metastasis to liver. Different degrees of lesions could be observed in nude mice, with silencing of ESM1 yielding improved lesions in liver and a lower number of lymph nodes (p < 0.05) (Fig-ure 6K ). Moreover, as immunohistochemistry and western blot assays demonstrated, silencing of ESM1 significantly downregulated the expression of ESM1 ( Figures 6L and 6M ). Therefore, silencing of ESM1 could inhibit bladder cancer distant metastasis and tumor formation in liver.
ESM1 and miR-9-3p were then decreased in bladder cancer cells to test this hypothesis ( Figures S4A-S4F ). There was no significant difference in the expression of ESM1, cell viability, apoptosis, migration, and invasion following the treatment of inhibitor miR-9-3p + si-ESM1 (p > 0.05). Therefore, silencing ESM1 could repress viability, apoptosis, migration, and invasion of bladder cancer cells.
Exosomal miR-9-3p Upregulation Inhibits Tumor Growth and Metastasis In Vivo
Xenograft tumor was used to determine the effect of exosomal miR-9-3p on tumor growth in nude mice. As shown in Figures 7A-7D , miR-9-3p expression was increased after the treatment of Exo-miR-9-3p (p < 0.05), whereas exosomal miR-9-3p upregulation decreased tumor growth, tumor volume, and tumor weight (p < 0.05). Moreover, the results of immunofluorescent staining demonstrated that exosomal miR-9-3p upregulation decreased MMP-2 and MMP-9 expression (p < 0.05) ( Figure 7E ). In addition, H&E staining was utilized to determined cancer metastasis to liver and lymph node metastasis. www.moleculartherapy.org
It was found that exosomal miR-9-3p elevation reduced lesions in the liver and number of lymph node metastasis (p < 0.05) ( Figure 7F ). Additionally, immunohistochemistry and western blot analysis were conducted to determine ESM1 protein expression ( Figures 7G  and 7H ). The results revealed that exosomal miR-9-3p elevation led to a reduction in ESM1 protein expression (p < 0.05). Meanwhile, opposite results were detected in the nude mice treated with exosomal miR-9-3p inhibitor, which further verified the above findings ( Figures  S5A-S5F ). Taken together, Exo-miR-9-3p upregulation inhibited tumor growth and metastasis in nude mice.
DISCUSSION
Genome-wide expression and sequencing analyses identify genes and pathways that are responsible for bladder cancer progression and understanding disease heterogeneity and molecular mechanisms. 15 Based on the data from two microarray gene expression profiles, GSE7476 and GSE37815, we identified that ESM1 was elevated in bladder cancer when compared with adjacent normal tissues. Exosomes have been recently recognized to regulate cell functions by transferring miRNAs. 16 Our data agreed with this concept that miR-9-3p upregulation in BMSC-derived exosomes in-hibited cellular progression and tumor growth in bladder cancer by targeting ESM1.
One of the important findings in the current study was that miR-9-3p elevation inhibited bladder cancer cell viability, migration, and invasion, and promoted its apoptosis. miRNAs are dysregulated in several urological cancers such as bladder, prostate, and renal cell cancer, and function as regulators of signal transduction. 17 Aberrant miR-9-3p expression has been observed in various types of malignant cancers, thus playing distinct roles in cancer progression. For example, miR-9-3p is proposed as a tumor promoter in medullary thyroid carcinoma cells. 18 In contrast, miR-9-3p acts as a tumor suppressor in other types of cancers. For instance, miR-9-3p reverses the EMT process and restrains proliferation and metastasis in nasopharyngeal carcinoma cells. 19 A transcriptome profile study reveals miR-9-3p as an anti-tumor miRNA that inhibits the invasion of gastric cancer cells. Additionally, miR-9-3p also augments H 2 O 2induced glioma cell apoptosis. 20, 21 These previous findings are consistent with our results that miR-9-3p elevation impaired bladder cancer cell viability, migration, and invasion, and enhanced its apoptosis. Another important finding of this study was that ESM1 was a target gene of miR-9-3p. Similarly, miR-9-3p exhibits a suppressive role in hepatocellular carcinoma by targeting TAZ (WWTR1). 22 Our study also found that ESM1 was expressed at a high level in bladder cancers, and this elevation increased bladder cancer cell viability, migration, and invasion, while inhibiting apoptosis. These findings suggest that ESM1 has an oncogenic property. TCGA bioinformatics database analysis displays that ESM1 is overexpressed in oral squamous cell carcinoma patients when compared with that in normal individuals. 23 Another study also shows that ESM1 exhibits an upregulated expression in prostate tumor tissues. 24 Further, high nuclear expression of ESM1 is detected in metastatic head and neck cancer cells. 25 In addition, a prior study demonstrates that upregulation of ESM1 mRNA level correlates with distant metastasis and vascular invasion in gastric cancer. 26 The same study also unravels that the loss of ESM1 reduces the proliferation and migration activity in head and neck cancer cells. 25 Moreover, ESM1 silencing inhibits colorectal cancer cell migration and invasion, 27 and suppresses hepatocellular carcinoma progression. 28 These findings strongly support our results that ESM1 silencing suppressed bladder cancer cell viability, migration, and invasion, and facilitated its apoptosis.
Our study further identified that miR-9-3p, delivered from BMSCderived exosomes, exerted anti-tumor effects in both bladder cancer cells and tumor-bearing nude mice. Similarly, exosomal miR-29c has been shown to trigger apoptosis of bladder cancer cells BIU-87 through negative regulation of Bcl-2 and MCL-1, thus preventing bladder cancer progression. 29 These results are consistent with a tumor-suppressive role of exosomal miR-9-3p in hepatocellular carcinoma. 13 This study further provided evidence that MSC-derived exosomes carrying miR-9-3p repressed liver and lymph node metastasis in mouse models. Furthermore, we also found that miR-9-3p reduced the expression of MMP-2 and MMP-9. MMP-2 and MMP-9 are known as markers of cell invasion. Similar to our results, miR-34a inhibits cell migration and invasion through downregulation of MMP-2 and MMP-9. 30 Additionally, overexpression of MMP-2 and MMP-9 is associated with lymph node metastasis in gastric cancer. 31 Therefore, our results provided evidence that exosomal miR-9-3p might exert anti-tumor effects by regulating MMP-2 and MMP-9, which deserved further investigation.
Taken together, results from this study demonstrated an anti-oncogenic role of miR-9-3p in bladder cancer by inhibiting a tumor promoter gene ESM1. Importantly, we demonstrated that miR-9-3p transferred through BMSC-derived exosomes prevented cancer progression and metastasis, which may provide insight on miRNA-based treatment for bladder cancer (Figure 8 ). However, the specific mechanism that underpins this process remains unclear, with further work required to consolidate this model.
MATERIALS AND METHODS

Ethical Statement
Written informed consent was obtained from all patients prior to the study. 
Microarray-Based Gene Expression Profiling
Bladder cancer-related microarray expression datasets were downloaded from GEO database (https://www.ncbi.nlm.nih.gov/geo/). The limma package of R language based on Bioconductor software was used to select differentially expressed genes (DEGs) in bladder cancer and control samples using the empirical Bayesian method. A heatmap of DEGs was also constructed with an annotated package of R language. p < 0.05 was considered with statistical significance throughout this study. miRDB (http://www.mirdb.org/), TargetScan (http://www.targetscan.org/vert_72/), and mirDIP (http://ophid. utoronto.ca/mirDIP/) databases were used to predict miRNAs that regulated ESM1. A Venn diagram was utilized to compare the predicted results.
Human Bladder Cell Lines
The bladder cancer tissues and adjacent normal tissues were collected from 30 patients who were hospitalized and confirmed as having purchased from American Type Culture Collection (Manassas, VA, USA). BMSCs were purchased from Shanghai Fusheng Biotechnology (Shanghai, China).
Cells were cultured with DMEM supplemented with 10% fetal bovine serum (FBS), 100 U/mL penicillin, and 100 mg/mL streptomycin (GIBCO, Gaithersburg, MD, USA) in a humidified incubator at 37 C with 5% CO 2 . Culture medium was replaced every 1-2 days. When cells reached 80%-90% confluence, cells were subcultured. The normal primary bladder epithelial cells were isolated and extracted by tissue block culture method as previously described. 33 qRT-PCR was used to determine miR-9-3p expression.
Collection of BMSCs in Mouse
Primary BMSCs were obtained from bilateral tibia and femur in the hind legs of specific pathogen-free (SPF) grade female BALB/c mice (age 4-6 weeks; weight 20-22 g; Hunan SLAC Laboratory Animal, Changsha, Hunan, China). Blood on the bone marrow cavity was washed repeatedly with DMEM with the aid of a 5-mL syringe. Bone marrow suspension was collected and placed in a 10-mL centrifugation tube, and centrifuged at 1,000 rpm for 5 min. After the supernatant was discarded, cells were resuspended in 3 mL of fresh DMEM medium containing 15% FBS. Cell density was adjusted to 1 Â 10 6 cells/mL for inoculation. Cells were then cultured in a culture bottle in an incubator. Cells at passages 2-3 were used for further experiments.
Cell Culture and Transfection
Bladder cancer cell lines UMUC-3 and T24 at logarithmic growth phase and with high expression of ESM1 were plated into a six-well plate (4 Â 10 5 cells/well). When cell confluence reached 70%-80%, cells were transfected according to the instructions of Lipofectamine 2000 (11668-019; Invitrogen, Carlsbad, CA, USA). Next, 200 mL serum-free Opti-MEM was used to dilute 10 mg plasmids (the final concentration into cells was 50 nM) and 5 mL Lipofectamine 2000, respectively. The above diluents were mixed, allowed to stand for 20 min, and cultured in a six-well plate at 37 C with 5% CO 2 and saturated humidity. After 48 h, cells were further cultured in a renewed DMEM containing 20% FBS for 24-48 h for later use. The sequences and plasmids for UMUC-3 transfection including si-negative control (NC), si-ESM1, mimic-NC, mimic miR-9-3p, inhibitor-NC, and inhibitor miR-9-3p were all purchased from Shanghai GenePharma (Shanghai, China).
Afterward, cells in the logarithmic growth phase were transduced with lentivirus when cell confluence reached 30%. Then 1 mL serum-free medium containing 100 U/mL penicillin/streptomycin was transduced with 2 Â 10 6 transducing units (TU) lentivirus and 8 mg/mL Polybrene (H9268; Sigma-Aldrich Chemical Company, St. Louis, MO, USA), which was observed under an inverted fluorescent microscope after 2-3 days. After 48 h, each well was added with 1 mg/ mL puromycin (P8833; Sigma-Aldrich Chemical Company, St. Louis, MO, USA) to screen out stably transduced cells, which were then cultured in conventional medium.
Subsequently, BMSCs were transduced with mimic miR-NSM, mimic miR-9-3p, inhibitor miR-NSM, and inhibitor miR-9-3p. After exosomes were derived from BMSCs, they were transduced with Exo-miR-NSM, Exo-miR-9-3p, inhibitor Exo-miR-NSM, and inhibitor Exo-miR-9-3p. qRT-PCR was conducted to determine the expression of miR-9-3p and ESM1.
Coculture of Bladder Cancer Cells and BMSCs or BMSC-Derived Exosomes
BMSCs were detached and plated in a 24-well plate (9 Â 10 3 cells/ well) and in a 6-well plate (4.5 Â 10 4 cells/well) (Millipore, Billerica, MA, USA), which were then cultured in DMEM low-glucose medium (the apical chamber). Meanwhile, bladder cancer cells were detached, plated in a 24-well plate (3 Â 10 3 cells/well) and in a 6-well plate (1.5 Â 10 4 cells/well), and cultured in DMEM (the basolateral chamber). After 24 h of culture, the complete medium was removed, and the plate and chambers were irrigated with serum-free DMEM. Cells were then cocultured in DMEM by placing chambers in the wells of culture plates. After that, the apical chamber was removed, and cells were used in subsequent experiments.
Next, BMSC-derived exosomes were incubated with the supernatant of the bladder cancer cell culture medium plated in a 24-well plate with 50%-60% cell confluence for 24 h. Then cells were treated with Exo-mimic-NSM, Exo-miR-9-3p, inhibitor Exo-NSM, and inhibitor Exo-miR-9-3p. qRT-PCR was performed to detect the expression of miR-9-3p and ESM1.
Fluorescent Labeling and Transfer of Exosomes
The extracted exosomes were labeled with the lipophilic dye PKH26 (red) liquor (MINI26-1KT; Sigma-Aldrich Chemical Company, St. Louis, MO, USA) at a working concentration of 10 mM and incubated at 37 C for 20 min. After rinsed by PBS, labeled exosomes were centrifuged at 4 C and 12,000 Â g for 70 min. The bladder cancer cells (3 Â 10 4 cells/well) grown on coverslips were incubated with PKH26labeled exosomes at a concentration of 25 mg/mL in a 24-well format for 24 h. Later, the cytoskeleton of bladder cancer cells was selectively stained with fluorescein isothiocyanate (FITC) phalloidin (Yeasen Company, Shanghai, China), resuspended in 500 mL PBS, and stained with DAPI. At last, the internalization of exosomes was measured using a confocal microscope.
Dual-Luciferase Reporter Gene Assay
To verify whether ESM1 was a direct target gene of miR-9-3p, we introduced synthesized ESM1 
Western Blot Analysis
Total proteins were extracted from cells, and their concentrations were determined using a BCA kit (Thermo Scientific, Wilmington, DE, USA). Proteins were then separated by PAGE and transferred onto a polyvinylidene difluoride membrane (Amersham Bioscience, Piscataway, NJ, USA). After blocked with 5% skimmed milk at room temperature for 1 h, the membrane was incubated with rabbit monoclonal antibody against CD9 (1:1,000, ab92726), CD81 (1:1,000, ab109201), CD63 (1:1,000, ab134045), TSG101 (1:1,000, ab125011), Ki67 (1:5,000, ab92742), MMP-2 (1:1,000, ab37150), and rabbit polyclonal antibody against Alix (1:1,000, ab76608), Calnexin (1:1,000, ab22595), PCNA (1:1,000, ab18197), MMP-9 (1:1,000, ab73734), and glyceraldehyde phosphate dehydrogenase (GAPDH; 1:1,000, ab37150) overnight at 4 C. The above antibodies were purchased from Abcam (Cambridge, UK). After washed by PBS containing 0.1% Tween 20 (TBST), the membrane was then further incubated with horseradish peroxidase (HRP)conjugated secondary goat anti-rabbit antibody against immunoglobulin G (IgG; 1:10,000; Jackson ImmunoResearch, West Grove, PA, USA) for 1 h at room temperature. After protein bands were visualized by an optical luminometer (GE Medical Systems, Milwaukee, WI, USA), relative protein expression in each band was measured by Image-Pro Plus 6.0 (Media Cybernetics, Rockville, MD, USA).
MTT Assay
Cells in the logarithmic growth phase were cultured for 24 h. Next, cells were washed twice in PBS, detached with 0.25% trypsin, and centrifuged at 1,000 rpm for 5 min. The uniform single-cell suspension was prepared by a pipette. Cells were then plated in a 96-well plate at the density of 5 Â 10 3 cells/well and cultured in an incubator at 37 C and with 5% CO 2 . Six parallel wells were set for each sample. After culture for 24, 48, 72, and 96 h, each well was incubated with 10 mL MTT solution in a 5% CO 2 incubator at 37 C for 2 h. Optical density (OD) in each well was detected at 450 nm by an automatic microplate reader (Multiskan MK3; Thermo, Waltham, MA, USA). The cell growth curve was plotted with the average OD value as the y label and time as the x label to calculate cell viability.
Scratch Test
After 48 h of transfection, cells were settled on the bottom of a six-well plate (Dow Corning, Midland, MI, USA). Cell surface was scratched with a 10-mL pipette head perpendicular to the plate. After washing with PBS three times, cells were added with serum-free DMEM (Nanjing SenBeiJia Biological Technology, Nanjing, China) for observation under an inverted microscope (XDS-800D; Shanghai Caikon Optical Instrument, Shanghai, China). Cells were then incubated for 24 h, and the healing of the scratch area was determined. Healing rate was calculated in three randomly selected visual fields, as the area at 24 h/the area at 0 h area.
Transwell Assay
After 48 h of transfection, cells were starved in serum-free medium for 24 h, washed twice with PBS, and resuspended in serum-free DMEM (Nanjing Sen BeiJia Biological Technology, Nanjing, China) containing 10 g/L BSA. Cell density was adjusted into 3 Â 10 4 cells/mL. The Transwell chamber was placed into a 24-well plate.
The apical membrane on the bottom of the Transwell chamber was covered by Matrigel (Millipore, Billerica, MA, USA). After standard detachment procedures, cells were rinsed twice with PBS and resuspended with DMEM, with cell density adjusted to 1 Â 10 5 cells/mL. Then 200-mL cell suspension was added to the apical chamber of the Transwell chamber, whereas 600 mL DMEM containing 20% FBS was added into the basolateral chamber. After 24 h of incubation, the Transwell chamber was removed and cells on the apical chamber were removed by cotton swabs. Cells were fixed with 4% paraformaldehyde, stained with 0.5% crystal violet solution, and washed three times with PBS for 15 min. Afterward, cells were observed and imaged in five randomly selected fields under an inverted microscope (XDS-800D; Shanghai Caikon Optical Instrument, Shanghai, China). The number of transmembrane cells was counted, and cell migration and invasion rate were calculated. ESM1, endothelial cell-specific molecule 1; F, forward; GAPDH, glyceraldehyde phosphate dehydrogenase; miR-9-3p, microRNA-9-3p; R, reverse.
